Studying the Effects of Denosumab on Female Ovary Function and Infertility Treatment by Modifying RANKL Signaling During Egg Development

What this Trial Is About

Female infertility is a significant challenge that is expected to worsen with delayed parenthood. Researchers are studying the role of receptor activator of NF-baB ligand RANKL in ovarian function and follicle development. This research explores whether blocking RANKL, using an antibody called denosumab which is currently used for osteoporosis, can help improve egg maturation and ovarian health in women undergoing fertility treatments. The study involves two main groups one receiving denosumab and the other receiving PBS as a comparison. It will test how modifying RANKL affects ovarian function in mice, monkeys, and human ovarian tissue, both systemically and locally. The research aims to clarify RANKLs role at different stages of follicle development and assess if manipulating this pathway can optimize in vitro egg maturation and fertility treatments. Participants, who are adult women with normal ovarian reserve, will be involved in evaluations including ovarian tissue studies and reproductive assessments. Researchers will monitor the impact of RANKL modification on ovarian function and follicle maturation throughout the study. The main measurements include reproductive characteristics in various animal models and human ovarian tissue to determine the effects of denosumab treatment from enrollment to study completion.

Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis